Robert L. Coleman

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

Robert L. Coleman, Michael W. Sill, Katherine M. Bell‐McGuinn et al. · Gynecologic Oncology · 2015 · 264 citations · Full text

Medicine, Oncology, Pharmacology +15

Intraoperative Lymphatic Mapping and Sentinel Node Identification with Blue Dye in Patients with Vulvar Cancer

C. Levenback, Robert L. Coleman, Thomas W. Burke et al. · Gynecologic Oncology · 2001 · 210 citations

Medicine, Oncology, Surgery +17

The Successful Implementation of Pharmaceutical Practice Guidelines 

David A. Lubarsky, Peter S. A. Glass, Brian Ginsberg et al. · Anesthesiology · 1997 · 147 citations · Full text

Medicine, Anesthesiology, Perioperative Medicine +16

Using an Anesthesia Information Management System as a Cost Containment Tool 

David A. Lubarsky, Iain Sanderson, William C. Gilbert et al. · Anesthesiology · 1997 · 82 citations · Full text

Computing, Anesthesiology, Health Informatics +16

Primary Neuroendocrine Carcinoma of the Vagina With Merkel Cell Carcinoma Phenotype

Neil M. Coleman, Megan J. Smith‐Zagone, János L. Tanyi et al. · The American Journal of Surgical Pathology · 2006 · 44 citations

Medicine, Oncology, Pathology +13